All data are based on the daily closing price as of May 16, 2025
s

Synmosa Biopharma

4114.TWO
1.11 USD
0.02
+1.83%

Overview

Last close
1.11 usd
Market cap
562.05M usd
52 week high
1.19 usd
52 week low
0.88 usd
Target price
1.19 usd

Valuation

P/E
20.2108
Forward P/E
N/A
Price/Sales
2.9636
Price/Book Value
2.068
Enterprise Value
545.14M usd
EV/Revenue
2.8804
EV/EBITDA
15.4441

Key financials

Revenue TTM
189.26M usd
Gross Profit TTM
81.85M usd
EBITDA TTM
36.58M usd
Earnings per Share
0.05 usd
Dividend
N/A usd
Total assets
412.15M usd
Net debt
4.53M usd

About

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, and other countries. Synmosa Biopharma Corporation was incorporated in 1980 and is headquartered in Taipei, Taiwan.
  • Symbol
    4114.TWO
  • Exchange
    TWO
  • Isin
    TW0004114004
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Banson Lin
  • Headquarter
    Taipei
  • Web site
    https://www.synmosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top